

---

# Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Eggermont AMM, Blank CU, Mandala M, et al. *N Engl J Med*. 2018;378(19):1789-1801.

Medical Writing Test

Emma Arigi, 2023.

# PEMBROLIZUMAB PROLONGED RECURRENCE-FREE SURVIVAL RELATIVE TO PLACEBO IN STAGE III MELANOMA

**EORTC 1325/ KEYNOTE-054 randomized, phase 3 trial of pembrolizumab 200 mg IV Q3W or placebo in patients with resected, high-risk, stage III melanoma**

## RFS at 12 Months

Overall ITT population  
(1019)

**43%  
RFS**

Patients in the pembrolizumab group had a 43% lower risk of recurrence or death than those in the placebo group.

(HR, 0.57; 98.4% CI, 0.43-0.74;  $P < .001$ )


Patients with PD-L1-  
positive tumors (853)

**46%  
RFS**

Patients in the pembrolizumab group had a 46% lower risk of recurrence or death than those in the placebo group.

(HR, 0.54; 95% CI, 0.42-0.69;  $P < .001$ )

## Treatment-Related Adverse Events in $\geq 10\%$ of Patients in Either Arm



HR=hazard ratio; IV=intravenously; PD-1=programmed cell death protein 1; PD-L1=programmed death-ligand 1; RFS=recurrence free survival; Q3W=every three weeks.  
Eggermont AMM, Blank CU, Mandala M, et al. *N Engl J Med.* 2018;378(19):1789-1801